2. >>Archive

Teva wins ruling over Coreg damages in US

 
• By Dean Rudge

Teva cannot be ordered to pay just over US$235 million in damages to GlaxoSmithKline (GSK) for infringing a method-of-use patent shielding the originator’s Coreg (carvedilol) antihypertensive, because “substantial evidence” does not support a federal jury’s earlier finding that Teva was liable for induced infringement through sales of its generic, a US district court has ordered.

Teva cannot be ordered to pay just over US$235 million in damages to GlaxoSmithKline (GSK) for infringing a method-of-use patent shielding the originator’s Coreg (carvedilol) antihypertensive, because “substantial evidence” does not support a federal jury’s earlier finding that Teva was liable for induced infringement through sales of its generic, a US district court has ordered.

In June last year, following a jury trial in a patent-infringement action over GSK’s reissued US patent RE40,000, jurors reached...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)